| I-33 Roberta Bartolucci Optimal design of paediatric clinical trials: the Macitentan case study Wednesday 09:50-11:15 |
| I-52 Ari Brekkan Viggosson Model based support to biosimilarity assessment planning – A case study of pegfilgrastim Wednesday 09:50-11:15 |
| I-88 Sofie Dhaese The use of optimal experimental design to inform a clinical trial on non-linearity of piperacillin clearance in critically ill patients. Wednesday 09:50-11:15 |
| II-45 France Mentré New version of PFIM for optimal design in nonlinear mixed effects models using R S4 Wednesday 15:10-16:40 |
| II-54 Flora Musuamba Tshinanu Dose optimization based on control and system theory: Case of Meropenem Wednesday 15:10-16:40 |
| II-80 Sudeep Pradhan Evaluation of study designs to test the intact nephron hypothesis Wednesday 15:10-16:40 |
| III-07 Daniel Röshammar Assessment of expected drug exposure relative maximum safety limits in early phase studies Thursday 09:55-11:20 |
| III-33 Suein Choi contribution of trough concentration data for the evaluation of multiple-dose pharmacokinetics Thursday 09:55-11:20 |
| IV-27 Peter Gennemark Determination of antisense oligonucleotide tissue half-life Thursday 15:25-16:50 |
